Nova Eye Medical (EYE) Discussion, page-702

Not surprised there are still a few cap raise investors lurking, regardless though this volume certainly helps flush them out for when news does come. Like you said, a sharp appreciation is never ideal, though I suspect it'll be able to hold onto the 30s especially if we see the buyers return into the close (fairly common for EYE)

Not sure about a US listing, doubt it as they have never been heavily reliant on raising lots of capital (which is often why US listings are beneficial). They'll likely be profitable soon enough on iTrack Advance that a US listing may be a waste (as they won't need to raise capital)